|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1501 M Street, NW |
Address2 | Suite 300 |
| City | Washington |
State | DC |
Zip Code | 20005 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Park Ridge |
State | IL |
Zip Code | 60068-2573 |
Country | USA |
|
5. Senate ID# 3388-12
|
||||||||
|
6. House ID# 315460000
|
||||||||
| TYPE OF REPORT | 8. Year | 2011 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Ronald Szabat, JD, LLM, Executive Vice President and General Counsel |
Date | 10/12/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 1044, Medicare Access to Rural Anesthesiology Act: Rural Pass Through
S. 848, Consumer Information Enhancement Act of 2011, Physician Data Reporting
S. 454, Strengthening Program Integrity in Health Care Act of 2011
S. 668, Health Care Bureaucrats Elimination Act
S. 365, Budget Control Act of 2011
H.R. 452, Medicare Decisions Accountability Act of 2011 - Independent Payment Advisory Board (IPAB) Repeal
H.CON.RES.34, Establishing the budget for the United States Government for fiscal year 2012 and setting forth appropriate budgetary levels for fiscal years 2013 through 2021. Medicare premium support issue
H.R. 2560, Cut, Cap, and Balance Act of 2011
Part B Medicare Physician's Fee Schedule: Implementation of Medicare Anesthesiology Teaching Funding Restoration Act
2012 Medicare Physician Fee Schedule proposed and final rules
Medicare Reform, Payment Issues: Medicare Sustainable Growth Rate repeal
Bundled payments
CMS Interpretive Guidelines: Hospital Conditions of Participation Related to Anesthesia Services
CMS Physician Resource Use Reports
CMS Hospital Outpatient Payment Proposed Rule
CMS Value-Based purchasing
Conditions of Participation - Anesthesia services, opt-outs, supervision
Physician Quality Report System, Quality, Sec. 3007 Quality Modifier
CMS E-Prescribing
President Obama's deficit reduction plans
Balance billing
MedPAC nominations
CMS Handoffs
Accountable Care Organizations
Historical Medicare payment undervaluation for anesthesiology services (33% problem)
Anesthesia Conversion Factor
Perioperative Home Model
Graduate Medical Education Cuts
Medicare Local Coverage Determinations
CMS MLN Critical Access Hospital Anesthesia Payment Rule
CMS Transcutaneous Electrical Nerve Stimulation comment letter
HHS Plan for Retrospective Review of Existing Rules 2011 - Conditions of Participation
CMS Five Year Review Proposed Rule
Value-based modifier - PPACA
5010 - Claims Processing
Debt ceiling- negotiation of Medicare re-entitlement reform
Gang of six - debt proposal
Coburn deficit reduction plan
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Government Accountability Office (GAO)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronald |
Szabat |
|
|
|
Manuel |
Bonilla |
|
|
|
Sharon |
Merrick |
|
|
|
Jason |
Byrd |
|
|
|
Michelle |
Mathy |
|
|
|
Traci |
Bone |
|
|
|
Lisa |
Pearlstein |
|
|
|
Grant |
Couch |
|
Senate Legislative Aide |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 451, Healthcare Truth and Transparency Act: Healthcare Provider Transparency, Healthcare Provider Misrepresentation
H.R. 866, National All Schedules Prescription Electronic Reporting Reauthorization Act
S. 296, Preserving Access to Life-saving Medications Act, drug shortages
Medical Liability Reform; H.R. 5, HEALTH Act of 2011
PPACA Nondiscrimination language regarding paraprofessionals - repeal
DEA Scheduling Propofol
Comparative Effectiveness Research
HITECH Implementation, Electronic Health Records, Final and Proposed Rules, HIT Meaningful Use
HHS/OIG Anesthesia Practice Arrangements, Company Model
FDA Risk Evaluation and Mitigation Strategies
FDA Safe Use Initiative
Pain Management
Individual Mandate- PPACA
Proposed Federal CME requirements by ONDCP
FDA Sedation Initiative
Drug Shortages - FDA, DEA, HHS, CMS
Scope of Practice
HIPAA Proposed Rule
FDA Operating Room Fires
FDA ACTION Initiative
FDA Sentinel
Prescription Drug User Fee Act
NASPER Funding; controlled substance abuse, misuse and diversion
State Exchanges pursuant to PPACA
FDA SEDASYS
FDA Sedation Products Request for Assistance
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Justice - Dept of (DOJ), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Office of Management & Budget (OMB), Executive Office of the President (EOP), Defense - Dept of (DOD), Occupational Safety & Health Administration (OSHA), Federal Trade Commission (FTC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronald |
Szabat |
|
|
|
Manuel |
Bonilla |
|
|
|
Sharon |
Merrick |
|
|
|
Jason |
Byrd |
|
|
|
Michelle |
Mathy |
|
|
|
Traci |
Bone |
|
|
|
Lisa |
Pearlstein |
|
|
|
Grant |
Couch |
|
Senate Legislative Aide |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
No lobbying activity in this issue area in Q3 2011.
17. House(s) of Congress and Federal agencies Check if None
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ronald |
Szabat |
|
|
|
Manuel |
Bonilla |
|
|
|
Sharon |
Merrick |
|
|
|
Jason |
Byrd |
|
|
|
Michelle |
Mathy |
|
|
|
Traci |
Bone |
|
|
|
Lisa |
Pearlstein |
|
|
|
Grant |
Couch |
|
Senate Legislative Aide |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
5 |
|
||||||
| 2 |
|
6 |
|
||||||
| 3 |
|
7 |
|
||||||
| 4 |
|
8 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 3 | 5 |
| 2 | 4 | 6 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 5 | 9 |
| 2 | 6 | 10 |
| 3 | 7 | 11 |
| 4 | 8 | 12 |